^Stähli BE, Tardif JC, Carrier M, Gallo R, Emery RW, Robb S, Cournoyer D, Blondeau L, Johnson D, Mann J, Lespérance J, Guertin MC, L'Allier PL. Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial. J. Am. Coll. Cardiol. January 2016, 67 (3): 344–6. PMID 26796402. doi:10.1016/j.jacc.2015.10.071.
^Morrison M, Palermo G, Schmitt C. Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects. Eur. J. Clin. Pharmacol. November 2015, 71 (11): 1365–74. PMID 26363899. S2CID 468125. doi:10.1007/s00228-015-1938-4.
^Schmitt C, Mudie N, Ciorciaro C, Gaudreault J. Absence of pharmacodynamic interaction between inclacumab and heparin in healthy smokers. J. Cardiovasc. Pharmacol. April 2015, 65 (4): 386–92. PMID 25602360. S2CID 19526048. doi:10.1097/FJC.0000000000000211.
^Tardif JC, Tanguay JF, Wright SR, Duchatelle V, Petroni T, Grégoire JC, Ibrahim R, Heinonen TM, Robb S, Bertrand OF, Cournoyer D, Johnson D, Mann J, Guertin MC, L'Allier PL. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J. Am. Coll. Cardiol. May 2013, 61 (20): 2048–55. PMID 23500230. doi:10.1016/j.jacc.2013.03.003.
^Kling D, Stucki C, Kronenberg S, Tuerck D, Rhéaume E, Tardif JC, Gaudreault J, Schmitt C. Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies. Thromb. Res. May 2013, 131 (5): 401–10. PMID 23522853. doi:10.1016/j.thromres.2013.02.020.